The Pharmaceutical Export Promotion Council of India (PHARMEXCIL) supported the India–Brazil Healthcare Business Gateway held at Taj Palace, New Delhi recently, bringing together Indian pharmaceutical manufacturers, regulatory authorities, and Brazilian healthcare leaders.
Organised by Amoveri Farma during the official visit of the Brazilian delegation, the closed-door meeting focused on expanding cooperation in oncology medicines, biosimilars, complex therapies, and hospital technologies, while facilitating structured access to the Brazilian market.
Pharmexcil Chairman Namit Joshi emphasised, “Brazil represents a significant opportunity for Indian MSME pharmaceutical manufacturers, particularly in specialty medicines, public healthcare supply, technology partnerships and regulatory collaboration. Indian companies possess the technological capability as well as the manufacturing scale required to expand high-quality medicines’ access for the Brazilian population. This meeting represents a strategic step toward deepening this pharmaceutical collaboration between India and Brazil. PHARMEXCIL remains committed to supporting initiatives that foster sustainable partnerships and facilitate responsible entry into the Brazilian market.”
iPHEX 2026, scheduled for 7-9 September 2026 is also set to serve as a global platform to showcase India's pharmaceutical capabilities, fostering innovation and international partnerships.
India's pharmaceutical exports to Brazil have shown significant growth, with the country currently ranked as the second-largest destination for Indian pharma exports by share.
Overall Export Performance (Values in $ Million) • FY 2024-25: Total exports reached $778.49 million, an 18.74% increase from $655.64 million in FY 2023-24. • Apr-Jan FY26 (Current Period): Exports totalled $740.33 million, reflecting a 17.03% growth compared to the $632.59 million recorded during the same period in FY25. • Market Share: Brazil accounts for approximately 2.88% of India's total country-wise pharmaceutical exports.
